An association between matrix metalloproteinase-2 and TIMP-2 +853G/A gene polymorphisms and multiple sclerosis;Asociace polymorfizmů v genu pro matrix metalloproteinázu-2 a tkáňový inhibitor metalloproteinázy-2 s roztroušenou sklerózou

Ceska a Slovenska Neurologie a Neurochirurgie

Volumn 75, Issue 3, 2012, Pages 314-319

  Benesova Y ^a   Vasku A ^b   Stourac P ^a,b   Hladikova M ^a   Okacova I ^a   Bednarik J ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Gene polymorphism; Matrix metalloproteinases; Multiple sclerosis

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DNA POLYMORPHISM; EXPANDED DISABILITY STATUS SCALE; GELATINASE A GENE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS SEVERITY SCORE; PHENOTYPE; POLYMERASE CHAIN REACTION; SCORING SYSTEM; SEX DIFFERENCE; TISSUE INHIBITOR OF METALLOPROTEINASE 2 GENE;

EID: 84863191063     PISSN: 12107859     EISSN: 18024041     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Hartung HP, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004; 251 (Suppl 5): v12-v29.
2. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52(1): 61-76. (Pubitemid 44466355)
3. Martin R, Bielekova B, Gran B, McFarland HF. Lessons from studies of antigenspecific T cell responses in multiple sclerosis. J Neural Transm Suppl 2000; 60: 361-373. (Pubitemid 32037207)
4. Hafler DA. Multiple sclerosis. J Clin Incest 2004; 113(6): 788-794. (Pubitemid 38544133)
5. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995; 201(3): 223-226. (Pubitemid 26009985)
6. Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as a major inflammatory mediators in multiple sclerosis. Brain 2003; 126(12): 2738-2749. (Pubitemid 37463092)
7. de Souza AP, Trevilatto PC, Scarel-Caminaga RM, Brito RB, Bartoš SP, Line SP. Analysis of the MMP-9 (C-1562T) and TIMP-2 (G-418C) gene promoter polymorphisms in patients with chronic periodontitis. J Clin Periodontol 2005; 32(2): 207-211. (Pubitemid 40341857)
8. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor U, Birkedal-Hansen B, DeCarlo A et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993, 4(2): 197-250. (Pubitemid 23103292)
9. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6(12): 931-944. (Pubitemid 41753087)
10. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993; 192(3): 1175-1181. (Pubitemid 23218538)
11. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998; 121(12): 2327-2334. (Pubitemid 28552469)
12. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006; 26(4): 299-307. (Pubitemid 44051377)
13. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998; 121(1): 159-166. (Pubitemid 28045514)
14. Galboiz Y, Shapiro S, Lahat N, Rawashden R, Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary progressive multiple sclerosis patients. Ann Neurol 2001; 50(4): 443-451. (Pubitemid 32938887)
15. Lindberg RL, De Groot CJ, Montagne L, Freitag P, VaIk P, Kappos L et al. The expression profile of matrix metalloproteinases (MMPs) and thein inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis Brain 2001; 124(9): 1743-1753. (Pubitemid 32845436)
16. Abraham M, Shapiro S, Karni A, Weiner HL, Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol 2005, 163(1-2): 157-164. (Pubitemid 40692958)
17. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006; 26(4): 299-307. (Pubitemid 44051377)
18. Sherer Y, Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev 2002; 1(1-2): 21-27. (Pubitemid 38367422)
19. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002; 33(11): 2711-2717. (Pubitemid 35266446)
20. Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Incest 1990; 86(5): 1496-1502. (Pubitemid 20372596)
21. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995; 154(9): 4379-4389.
22. Montgomery AM, Sabzevari H, Reisfeld RA. Production and regulation of gelatinase B by human T-cells. Biochim Biophys Acta 1993; 1176(3): 265-268 (Pubitemid 23113768)
23. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55(3): 300-309. (Pubitemid 26085579)
24. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136(1-2): 46-53. (Pubitemid 36298843)
25. Benesová Y, Vasku A, Novotná H, Litzman J, Stourač P, Beránek M et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler 2009; 15(3): 316-322.
26. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997; 23(5): 406-415. (Pubitemid 27440481)
27. Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM. Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol 2006; 111(4): 289-299.
28. Fainardi E, Castellazzi M, Tamborino C, Trentini A, Manfnnato MC, Tola MR et al. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult Scler 2009, 15(5): 547-554.
29. Borden P, Keller RA. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Cit Rev Eukaryot Gene Expr 1997; 7(1-2): 159-178. (Pubitemid 27148904)
30. Yushchenko M, Mäder M, Elitok E, Bitsch A, Dressel A, Tumani H et al. Interferon-beta-1b decreased matrixmetalloproteinase-9 serum levels in primary progressive multiple sclerosis J Neurol 2003; 250(10): 1224-1228. (Pubitemid 37289657)
31. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl) mercuric acetate. Biochemistry 1990; 29(24): 5783-5789. (Pubitemid 20192450)
32. Bernardo MM, Fridman R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 2003; 347(3): 739-745 (Pubitemid 37163919)
33. Benesová Y, Vasků A, Stourač P, Hladí ková M, Beránek M, Kadanka Z et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis J Neuroimmunol 2008; 205(1-2): 105-109.
34. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58(6): 840-846 (Pubitemid 41746873)
35. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33(11): 1444-1452. (Pubitemid 14237132)
36. Roxburgh RH, Seman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple Sclerosis Seventy Score: using disability and disease duration to rate disease severity. Neurology 2005; 64(7): 1144-1151.
37. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele specific transcriptional regulation. J Biol Chem 2001; 276(10): 7549-7558.
38. Vasků A, Goldbergová M, Izakovicová Hollá L, Sisková L, Groch L, Beránek M et al. A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306GT, -790 T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol 2004; 22(7): 585-591. (Pubitemid 38283782)
39. Xu E, Xia X, Lu B, Xing X, Huang Q, Ma Y et al. Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog 2007; 46(11): 924-929. (Pubitemid 350058412)
40. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004; 64(20): 7622-7628. (Pubitemid 39372109)
41. Zhou Y, Yu C, Miao X, Wang Y, Tan W, Tong S et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility Carcinogenesis 2005; 26(6): 1117-1121. (Pubitemid 41214305)
42. Rollin J, Régina S, Vourc'h P, lochmann S, Bléchet C, Reverdiau P et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007; 56(2): 273-280. (Pubitemid 46591988)
43. Nemec P, Goldbergová M, Svobodnik T, Polásková D, Soucek M, Vasků A. Polymorphism of gene promotor region for MMP-2 in rheumatoid arthritis. Vnitr Lek 2006; 52(4): 348-354.
44. Hirano K, Sakamoto T, Uchida Y, Morishima Y, Masuyama K, Ishii Y et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001; 18(5): 748-752. (Pubitemid 33076914)
45. Wang X, Tromp G, Cole CW, Verloes A, Sakalihasan N, Yoon S et al. Analysis of coding sequences for tissue inhibitor of metalloproteinases 1 (TIMP1) and (TIMP2) in patients with aneurysms. Matrix Biol 1999; 18(2): 121-124. (Pubitemid 29229696)
46. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH. T-cell and macrophage mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 2001; 124(11): 2203-2214. (Pubitemid 33055365)
47. Ebers G. Genetic factors in multiple sclerosis. MS Forum; Modern Management Workshop Boston 1995.
48. Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, Akesson E, Palmgren J. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PloS One 2007; 2(7): e664.
49. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al. Multiple Sclerosis Genetics Group. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39(9): 1083-1091. (Pubitemid 47340652)